Wipro surges on entering into four-year strategic alliance with Avesthagen
Wipro is currently trading at Rs. 422.65, up by 8.15 points or 1.97% from its previous closing of Rs. 414.50 on the BSE.
The scrip opened at Rs. 420.00 and has touched a high and low of Rs. 423.20 and Rs. 416.65 respectively. So far 55540 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 739.80 on 14-Oct-2021 and a 52 week low of Rs. 402.10 on 17-Jun-2022.
Last one week high and low of the scrip stood at Rs. 450.65 and Rs. 402.10 respectively. The current market cap of the company is Rs. 227242.91 crore.
The promoters holding in the company stood at 73.00%, while Institutions and Non-Institutions held 11.36% and 13.18% respectively.
Wipro and Avesthagen have entered into a four-year strategic alliance, for making Avesthagen’s genetic testing portfolio commercial. The portfolio includes genome panels offering highly specific, disease-centric analysis for conditions including cancers, neurodegenerative diseases, autoimmune disorders and rare disease conditions.
Together, Avesthagen and Wipro will execute the project titled, ‘Cancer Risk Assessed by NGS profiling of Circulating free DNA and RNA for Lung Cancer Project related Genomics Sequencing services.’ The Project will be jointly led by Avesthagen and Wipro where Wipro’s state-of-the-art Lifesciences lab will perform initial processing of the samples, generate data on the latest Next-generation sequencing platforms, compile genomic sequences and analyze detailed molecular information using computational AI/ML based tools.
Wipro is a leading global information technology, consulting and business process services company.
